Kenneth Carl Anderson
Dana-Farber Cancer Institute
Public scientific profile · Unclaimed
Built from public scholarly sources. Expertise is inferred by ScienceWe from publications and has not been confirmed by the scientist.
Top expertise
Multiple Myeloma Research and Treatments
Strong evidence · 8 supporting papers · latest 2026
Ubiquitin and proteasome pathways
Strong evidence · 2 supporting papers · latest 2026
CAR-T cell therapy research
Strong evidence · 4 supporting papers · latest 2026
Chronic Lymphocytic Leukemia Research
Strong evidence · 1 supporting paper · latest 2026
Protein Degradation and Inhibitors
Solid evidence · 4 supporting papers · latest 2026
Acute Myeloid Leukemia Research
Solid evidence · 3 supporting papers · latest 2026
Immunotherapy and Immune Responses
Solid evidence · 2 supporting papers · latest 2026
PI3K/AKT/mTOR signaling in cancer
Solid evidence · 1 supporting paper · latest 2026
Publications (12)
Genomically Smoldering Multiple Myeloma Is Not a Distinct Entity But a Collection of Monoclonal Gammopathy of Undetermined Significance or Multiple Myeloma
2025DOIPMID 41380103
Proteasome subunit PSMD1 is a key therapeutic target in multiple myeloma
2026DOIPMID 41632828
Continuous or Fixed-Duration Maintenance Therapy in Multiple Myeloma
2026DOIPMID 42456135
WNK2 oncogenicity revealed by the discovery and functional characterization of novel gene isoforms in MYD88 mutated Waldenström’s Macroglobulinemia
2026DOIPMID 42420257
Abstract CT103: Ciltacabtagene autoleucel in high-risk smoldering myeloma: Results from the CAR-PRISM trial
2026DOI
RVd and CyBorD therapies remodel B-cell maturation signaling and alter immune and clonal architecture in multiple myeloma
2025DOIPMID 41410549
Rethinking Multiple Myeloma Treatment: The Biological and Clinical Insights Guiding Immune-Based Combinations
2026DOIPMID 41636424
The International Myeloma Society Honors the Life and Legacy of Myeloma Pioneer Brian G. M. Durie, MD, PhD (1942–2025)
2026DOIPMID 42103397
Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial
2026DOIPMID 42010117
The role of RAD23A in DNA repair and proteasome-dependent protein degradation in multiple myeloma
2026DOIPMID 42457667
A first-in-class RNA degrader reduces c-MYC expression and myeloma cell survival in preclinical models
2026DOIPMID 42526890
Group Authors List 1 from Cancer in 2025
2025DOI
Organizations in sourced records
Affiliation evidence only — not confirmed current employment.
- Dana-Farber Cancer Institute
Source: OpenAlex · retrieved 2026-09-29